Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memocycline: Minocycline for Reconsolidation of Intrusive Memories in PTSD and CUD
NCT05902819Completed
- Sponsor
- Psychiatrische Universitätsklinik Zürich
- Start
- May 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of minocycline in post-traumatic stress disorder (PTSD) and cocaine use disorder (CUD) (6 arms), sponsored by Psychiatrische Universitätsklinik Zürich. Primary endpoints: Changes in intrusive memories frequency and features at 3.5 months and Change over time in self-reported intrusive memories frequency, arousal and distress. Started May 2023; status: completed.
02
Drugs
minocycline
03
Conditions
post-traumatic stress disorder (PTSD)cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT05902819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902819.